Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: ChemTrak

This article was originally published in The Gray Sheet

Executive Summary

ChemTrak: Reacquires from Astra Merck exclusive U.S. marketing rights to its Hp Chek rapid whole blood H. pylori test. Astra Merck, which will pay ChemTrak $2.4 mil. to return the rights, retains an option to obtain non-exclusive distribution rights in the future. Astra Merck, which offers its Prilosec (omeprazole) drug for ulcer treatment, notes that "many more prescriptions for Prilosec are written to treat gastroesophageal reflux disease," and says it has decided to "focus on the core business." The test gained 510(k) clearance in June 1996 ("The Gray Sheet" July 8, 1996, In Brief)...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT008840

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel